-
Oil, stocks mixed as traders weigh outlook after Trump extends truce
-
Anthropic probes unauthorized access to Mythos AI model
-
Stadium that was symbol of NZ post-quake rebuild to hold first match
-
Blazers stun Spurs after Wemby injury, Lakers down Rockets
-
Chinese carmakers aim to build up presence in Europe
-
Maoist landmine legacy haunts India
-
Fiji villagers reject plan for 'Pacific ashtray' in beach paradise
-
India orders school water bells to beat heat
-
Japanese minnows one win from fairytale Champions League title
-
Rugby Australia eyes brighter future as Lions tour brings cash windfall
-
Blazers rally stuns Spurs after Wembanyama injury
-
Young Chinese use AI to launch one-person firms over job anxiety
-
Delicate extraction: Malaysia offers rare earths alternative to China
-
Oil, stocks fall as traders weigh outlook after Trump extends truce
-
Pope to visit prison on final leg of Africa tour
-
US military says key weapons system staying in South Korea
-
India strangles final Maoist bastion as mining looms
-
AI-powered robots offer new hope to German factories
-
Indonesia orangutan forest cleared for 'carbon-neutral' packaging firm
-
PGA Tour mulls pathway back for golfers as LIV plots survival
-
One month phone-free: Young Americans try digital detox
-
Questions about Tesla spending binge ahead of earnings
-
Rome summons Russian ambassador over insults against Meloni
-
US tells Afghans to choose Taliban home or DR Congo: activist
-
John Ternus to lead Apple in the age of AI
-
SpaceX partners with AI startup Cursor, may buy it for $60 bn
-
Mexico pyramid shooter inspired by Columbine attack, pre-Hispanic sacrifices
-
Mexico pyramid shooter planned attack, fixated on US massacre
-
Mbappe on the mark as Real Madrid sink Alaves
-
Rosenior blasts Chelsea flops after 'unacceptable' Brighton defeat
-
Inter roar back to beat Como and reach Italian Cup final
-
Lens sweep past Toulouse to reach French Cup final
-
Brighton crush Chelsea to pile pressure on under-fire Rosenior
-
Strait of Hormuz blockade drives up costs at Panama Canal
-
Trump extends ceasefire, says giving Iran time to negotiate
-
Michelle Bachelet hopes the world is ready for a female UN chief
-
Nowitzki, Bird among eight inductees into FIBA Hall of Fame
-
Stocks fall, oil climbs amid uncertainty over US-Iran talks
-
Iran war means more orders for US defense giants
-
Mexico pyramid shooting was planned attack, officials say
-
Trump's messaging on Iran grows increasingly erratic
-
Churchill Downs buys Preakness for $85 million
-
Unregulated AI like speeding with no steering wheel: AI godfather Hinton
-
Tourists return to Rio viewpoint after shootout scare
-
Maradona's daughter slams 'manipulation' of family by his doctors
-
Abhishek's 135 powers Hyderabad to third straight IPL win
-
Vance still in Washington as uncertainty mounts over US-Iran talks
-
No.1 Jeeno seeks first major win at LPGA Chevron event
-
New batch of World Cup tickets to go on sale
-
Material girl: Madonna offers reward for missing clothes
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
S.Gantenbein--VB